Indaptus Therapeutics, Inc. (INDP) intrinsic value & 10-year financials
Indaptus Therapeutics, Inc. (INDP) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.63
- Market cap
- $2.5M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 422.4%
- Free cash flow (FY2025)
- —
INDP 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$20.8M | -$21.58 | — | — | -559.0% |
| FY2024 | — | -$15.0M | -$1.61 | — | — | 1267.6% |
| FY2023 | — | -$15.4M | -$1.83 | — | — | 1351.1% |
| FY2022 | — | -$14.3M | -$1.73 | — | — | 471.9% |
| FY2021 | — | -$7.7M | — | -$11.3M | — | 244.6% |
| FY2020 | — | -$3.6M | — | — | — | -242.2% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Indaptus Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Indaptus Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just 4.2% ROIC.
Indaptus Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Indaptus Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.